BioSymetrics

BioSymetrics is an AI/ML-enabled drug discovery company tackling the high failure rate in clinical trials by connecting human phenotypic and genotypic data with in vivo validation in model systems. The company's proprietary platform, Elion, uses patented Contingent AI™ and zebrafish phenotypic models to rapidly identify and validate novel therapeutic targets. With a pipeline initially focused on epilepsies and partnerships providing access to massive datasets, BioSymetrics aims to de-risk the early discovery process and deliver more translatable candidates.

Elion platform: A phenomics-driven platform integrating patented Contingent AI™ for virtual phenotypic screening and target prediction with high-throughput in vivo validation using zebrafish models and computer vision analysis.

BioSymetrics competes in the crowded AI/ML drug discovery sector with companies like Recursion, Exscientia, and Insitro. Its differentiation lies in its specific focus on phenomics—connecting human clinical phenotypes to model organism data—and its closed-loop integration of AI with high-content zebrafish validation.